Sales of Antiretroviral Drugs for HIV Will Decrease Marginally Over the Next Decade, from an Estimated $13.4 Billion in 2012 to

 Sales of Antiretroviral Drugs for HIV Will Decrease Marginally Over the Next
   Decade, from an Estimated $13.4 Billion in 2012 to $13.1 Billion in 2022

The Strongest Dynamic Decreasing Sales in the HIV Market is Generic Erosion of
Key Antiretroviral Drugs, According to a New Report from Decision Resources

PR Newswire

BURLINGTON, Mass., Dec. 4, 2013

BURLINGTON, Mass., Dec. 4, 2013 /PRNewswire/ --Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that major-market sales of antiretroviral (ARV) drugs for HIV
will decrease marginally over the next decade, from an estimated $13.4 billion
in 2012 to $13.1 billion in 2022 in the United States, France, Germany, Italy,
Spain, the United Kingdom and Japan.

(Logo: )

The Pharmacor advisory service entitled Human Immunodeficiency Virus (HIV)
finds that the strongest factor constraining the HIV therapy market is the
generic erosion of numerous key ARV drugs, such as efavirenz (Bristol-Myers
Squibb's Sustiva, Merck/Banyu's Stocrin), tenofovir disoproxil fumarate [TDF]
(Gilead/Japan Tobacco's Viread), atazanavir (Bristol-Myers Squibb's Reyataz),
darunavir (Janssen's Prezista), emtricitabine/TDF (Gilead/Japan Tobacco's
Truvada) and efavirenz/emtricitabine/TDF (Gilead/ Bristol-Myers Squibb's
Atripla). Increasing availability of generics in cost-constrained markets will
inhibit uptake of new, higher-priced agents and is responsible for decreased
ARV sales in major pharmaceutical markets, particularly European markets where
the impact of generic erosion will be the heaviest. Notably, all three active
pharmaceutical agents in the 2012 sales leader, Gilead/ Bristol-Myers Squibb's
single-tablet regimen (STR) Atripla will lose patent protection during the
2012 to 2022 forecast period, paving the way for generic STR prescribing in
the major markets.

A key driver of sales growth in the HIV market is the increasing uptake of
new, premium-priced agents, including integrase inhibitors and integrase
inhibitor-based STRs. Diagnosis will also increase owing to broadening
screening efforts and an expansion of the treatment-eligible population as a
result of treatment guidelines urging treatment for HIV patients irrespective
of CD4 cell levels, particularly in the United States.

The findings also reveal that, of the emerging therapies, the recently
launched integrase inhibitor dolutegravir (ViiV's Tivicay) is best poised for
commercial success during the 2012-2022 forecast period. ViiV is already
marketing dolutegravir as a stand-alone product that can be used with
different NRTI backbone regimens in the United States and has submitted
regulatory filings to the EMA to support this usage.

"Uptake of dolutegravir will be somewhat constrained by the availability of
generics for heavily prescribed, currently marketed ARV drugs such as Atripla
and Gilead's newly available integrase inhibitor- based STR Stribild," said
Decision Resources Analyst Seamus Levine-Wilkinson, Ph.D. "Nevertheless,
dolutegravir's strong clinical profile will enable this agent to achieve
blockbuster status as both a stand-alone agent and as a component of the
recently filed 572-Trii STR."

About Decision Resources
Decision Resources ( is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Contact: Decision Resources Group, Christopher Comfort, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.